GMP – Page 44 – Pharma.Tips

Inadequate WHO GMP training during remediation planning – evidence pack for WHO audits

“`html Mitigating Inadequate WHO GMP Training in Remediation Planning for Effective Audits Inadequate training in WHO GMP practices can lead to critical issues during remediation planning, negatively impacting compliance and…

Redundant cleaning steps during multi-product campaigns – validated efficiency improvement

Enhancing Efficiency by Addressing Redundant Cleaning Steps in Multi-Product Campaigns In pharmaceutical manufacturing, particularly during multi-product campaigns, redundant cleaning steps can lead to significant inefficiencies. These redundancies can extend the…

Documentation not aligned to WHO during API sourcing – WHO inspector expectations explained

Aligning Documentation with WHO Standards During API Sourcing: A Practical Playbook Ensuring compliance with WHO documentation standards during the active pharmaceutical ingredient (API) sourcing process is critical for maintaining quality…

Documentation not aligned to WHO during internal gap assessment – avoiding repeat WHO observations

Addressing Documentation Gaps in WHO Compliance: A Playbook for Pharma Professionals Non-compliance with WHO guidelines during internal gap assessments can lead to significant regulatory observations, impacting both operational efficiency and…

API site WHO GMP risk during remediation planning – CAPA aligned to WHO standards

Managing WHO GMP Risks in API Sites During Remediation Planning: A Practical Playbook In the pharmaceutical industry, maintaining Good Manufacturing Practices (GMP) is paramount, especially in Active Pharmaceutical Ingredient (API)…

Extended cleaning duration during multi-product campaigns – inspection-ready cleaning optimization

Optimizing Cleaning Processes to Address Extended Durations in Multi-Product Campaigns Extended cleaning durations can pose significant challenges in pharmaceutical manufacturing, especially during multi-product campaigns. This situation can lead to increased…

Supplier WHO GMP non-compliance during API sourcing – evidence pack for WHO audits

Effective Playbook for Managing WHO GMP Non-Compliance in API Sourcing Non-compliance with WHO Good Manufacturing Practices (GMP) during Active Pharmaceutical Ingredient (API) sourcing can have significant repercussions, from failed audits…

Supplier WHO GMP non-compliance during WHO inspection – gap remediation roadmap

Remediation Roadmap for Supplier WHO GMP Non-Compliance During Inspection Supplier WHO GMP non-compliance can pose significant risks during inspections, especially under the scrutiny of WHO PQ standards. Manufacturing facilities may…

Inadequate WHO GMP training during API sourcing – evidence pack for WHO audits

Addressing Insufficient WHO GMP Training in API Sourcing: A Comprehensive Playbook Inadequate WHO GMP training during API sourcing presents significant risks for pharmaceutical manufacturers, impacting compliance with international standards and…

Extended cleaning duration during validation lifecycle – cycle time reduction with compliance assurance

Reducing Cleaning Cycle Time During Validation Without Compromising Compliance In the ever-evolving landscape of pharmaceutical manufacturing, optimizing cleaning processes is a critical component of both operational efficiency and regulatory compliance.…

API site WHO GMP risk during API sourcing – CAPA aligned to WHO standards

Managing WHO GMP Risks During API Sourcing: An Actionable Playbook The procurement of Active Pharmaceutical Ingredients (APIs) from external suppliers poses significant risks related to WHO GMP compliance. Understanding these…

Documentation not aligned to WHO during API sourcing – avoiding repeat WHO observations

Ensuring Documentation Alignment with WHO Guidelines During API Sourcing Non-compliance with WHO GMP guidelines during Active Pharmaceutical Ingredient (API) sourcing can lead to significant regulatory observations and consequences. This article…